Clinical Trial Update: A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia [Phase 1]

View source ↗

Summary

Pfizer completed a Phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of PF-06412562 in adults with schizophrenia; results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• PF-06412562 (PF-06412562)

Snippet

Sponsor: Pfizer | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2019-02-04